Trial Profile

A Phase III Confirmatory Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linzagolix (Primary)
Indications Uterine leiomyoma
Focus Registrational; Therapeutic Use
Sponsors Kissei Pharmaceutical

Most Recent Events

14 Mar 2025 Status changed from active, no longer recruiting to completed.
18 Jul 2024 According to a Kissei Pharmaceutical media release, detailed results of these studies are currently being analyzed.
18 Jul 2024 Primary endpoint has been met. (Proportion of subjects with a total PBAC score of less than 10 from Week 6 to 12 after beginning of study drug administration), according to a Kissei Pharmaceutical Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com